Trichy Daily

Asthma Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Asthma Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight

November 09
18:08 2022
Asthma Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Asthma Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

 

Key takeaways from Asthma Pipeline Insight Report

 

  • DelveInsight’s Asthma Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Asthma.
  • The leading Asthma Companies such as Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others are developing therapies for the Asthma treatment.
  • Promising Asthma Pipeline therapies such as A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The therapies under development are focused on novel approaches to treat/improve Asthma.
  • In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

 

Request a sample and discover the recent advances in Asthma treatment @ Asthma Pipeline Report

 

 

Asthma Overview

 

Asthma is a chronic disease that affects the airways.  Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath, and chest tightness. Symptoms of asthma vary from person to person. A person may have infrequent asthma attacks or have symptoms only at a certain time such as when exercising or may have symptoms all the time. Symptoms of asthma resemble many respiratory infections. The first step in asthma diagnosis is a careful clinical history; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on the quality of life.

 

 

Recent Breakthroughs of Asthma Treatment Landscape

 

  • In October 2021, The board of directors of Mabpharm Limited announced that the new drug application (NDA) of CMAB007 (omalizumab), a core product of the Company, was accepted by the National Medical Products Administration of the People’s Republic of China (“NMPA”) for the treatment of allergic asthma, which is the first domestic allergic asthma therapeutic antibody new drug in China with NDA submitted. CMAB007 (omalizumab) is the second drug to be submitted for marketing application by the Company.
  • In September 2021, Evelo Biosciences, Inc. announced that the U.S. Patent and Trademark Office has issued a new composition of matter patent (No. 11,090,341) for medicines comprising pharmaceutical compositions of Veillonella parvula bacteria. This patent is a key addition to the Company’s substantial and growing intellectual property (IP) portfolio for treatments targeting the small intestinal axis, SINTAX™.
  • In November 2021, CSPC Pharmaceutical Group Limited (the “Company” announced that Shanghai JMT-BIO Technology Co., Ltd, a wholly-owned subsidiary of the Company, has entered into an agreement (the “Agreement”) with Keymed Bioscience (Chengdu) Co., Ltd. in relation to the exclusive licensing and commercialization of the product CM326 (an anti-TSLP recombinant humanized monoclonal antibody, the “Product”) in the treatment of moderate to severe asthma, chronic obstructive pulmonary disease (COPD) and other respiratory system diseases.
  • In November 2021, Amgen and AstraZeneca agreed to include AMG 104 / AZD8630 in the existing collaboration agreement between the parties. AMG 104 / AZD8630 becomes part of the collaboration with the companies sharing both costs and income, with no inventor royalty.

 

 

Find out more about Asthma Medication @ Asthma Treatment

 

 

Asthma Emerging Drugs

 

  • PT-027: Avillion LLP
  • MM09-MG01: Inmunotek S.L.
  • FP 025: Foresee Pharmaceuticals
  • GB001: Gossamer Bio
  • EDP1867: Evelo Biosciences, Inc.
  • TQC2731: Chia Tai Tianqing Pharmaceutical Group

 

 

DelveInsight’s Asthma Pipeline Report covers around 100+ products under different phases of clinical development like

 

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Learn more about the novel and emerging Asthma pipeline therapies @ Asthma Clinical Trials

 

 

Scope of the Asthma Pipeline Report

 

  • Coverage- Global
  • Asthma Pipeline Assessment by Product Type
  • Asthma Pipeline Assessment by Stage and Product Type
  • Asthma Pipeline Assessment by Route of Administration
  • Asthma Pipeline Assessment by Stage and Route of Administration
  • Asthma Pipeline Assessment by Molecule Type
  • Asthma Pipeline Assessment by Stage and Molecule Type
  • Asthma Companies- Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others
  • Asthma Therapies- A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others

 

 

Table of content

 

  1. Introduction
  2. Executive Summary
  3. Asthma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Asthma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. PT-027: Avillion LLP
  9. Mid Stage Products (Phase II/III)
  10. PT001: Pearl Therapeutics (AstraZeneca)
  11. Mid Stage Products (Phase II)
  12. FP 025: Foresee Pharmaceuticals
  13. Early Stage Products (Phase I/II)
  14. AQ-001S: Aquilon Pharmaceuticals S.A
  15. Early Stage Products (Phase I)
  16. Itolizumab (EQ001): Equillium
  17. Preclinical and Discovery Stage Products
  18. KBP7026: KBP Biosciences
  19. Inactive Products
  20. Asthma Key Companies
  21. Asthma Key Products
  22. Asthma- Unmet Needs
  23. Asthma- Market Drivers and Barriers
  24. Asthma- Future Perspectives and Conclusion
  25. Asthma Analyst Views
  26. Asthma Key Companies
  27. Appendix

 

 

Dive deep into rich insights for drugs for Asthma treatment, visit @ New Drug for Asthma Treatment

 

 

About Us

 

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles